Last $1.70 USD
Change Today -0.05 / -2.86%
Volume 672.8K
CRIS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Open
$1.75
Previous Close
$1.75
Day High
$1.77
Day Low
$1.67
52 Week High
10/2/13 - $4.74
52 Week Low
08/22/14 - $1.53
Market Cap
146.2M
Average Volume 10 Days
906.9K
EPS TTM
$-0.15
Shares Outstanding
86.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

33 Employees
Last Reported Date: 03/13/14
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Curis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $4,801,285 compared to $5,404,377 a year ago. Net loss from operations was $1,544,787 compared to $706,196 a year ago. Net loss was $1,895,785 or $0.02 per basic and diluted share compared to $1,293,848 or $0.02 per basic and diluted share a year ago. The decrease in Revenue was primarily due to a $1 million decrease in license revenue due to $3 million and $4 million milestone payments Curis earned from Genentech/Roche upon achievement by Genentech/Roche of certain development objectives during the second quarters of 2014 and 2013, respectively. For the six months, the company reported total revenues of $6,085,918 compared to $6,275,812 a year ago. Net loss from operations was $6,298,130 compared to $5,063,560 a year ago. Net loss was $7,459,721 or $0.09 per basic and diluted share compared to $6,256,142 or $0.08 per basic and diluted share a year ago.

Curis, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Curis, Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 07, 2014

Curis, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Curis, Inc., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $1.70 USD -0.05

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.29 USD -0.03
Cytokinetics Inc $4.07 USD -0.21
Delcath Systems Inc $2.57 USD +0.17
MELA Sciences Inc $2.34 USD -0.01
Navidea Biopharmaceuticals Inc $1.40 USD -0.03
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit www.curis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.